Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800269 | 0.89 | ALDH1A1 (0.38) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL6793350 | 0.80 | PIK3CD (0.36) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL6798186 | 0.77 | ALDH1A1 (0.38) | CCNA2CDK2CCNA1 | |
| SCHEMBL6788857 | 0.74 | ALDH1A1 (0.36) | CCNA2CDK2CCNA1 | |
| SCHEMBL6789502 | 0.74 | SMN1; SMN2 (0.41) | RAB9A | |
| SCHEMBL6790555 | 0.71 | CCNA2 (0.40) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL6790817 | 0.71 | DRD2 (0.35) | CCNA2CDK2CCNA1 | |
| SCHEMBL6791828 | 0.70 | CDK2 (0.45) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL6793099 | 0.67 | LMNA (0.36) | RAB9A | |
| SCHEMBL6794681 | 0.66 | DRD2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.